#GynCSM Transcript
Healthcare social media transcript of the #GynCSM hashtag.
– ().
See #GynCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | GYN Cancer | #GYNCSM @gyncsm Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
 | Dee Sparacio @womenofteal RT @gyncsm: Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
| GYN Cancer | #GYNCSM @gyncsm Our #gyncsm co-moderators are @womenofteal @btrfly12 Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte |
 | Sarah Temkin @temkins RT @gyncsm: Our #gyncsm co-moderators are @womenofteal @btrfly12 Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte |
| GYN Cancer | #GYNCSM @gyncsm We start out with brief intro’s - Please take a moment to introduce yourself. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Our #gyncsm co-moderators are @womenofteal @btrfly12 Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte |
| Dee Sparacio @womenofteal RT @gyncsm: We start out with brief intro’s - Please take a moment to introduce yourself. #gyncsm |
 | Olga Ioffe 🇺🇦 @oioffe RT @gyncsm: Our #gyncsm co-moderators are @womenofteal @btrfly12 Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte |
| GYN Cancer | #GYNCSM @gyncsm We are so pleased to have Kim @KDRichardson924 along with Ben, Tova and Casey from @UICMSTP joining us to discuss the newly released "Survivors Advising Scientists Educational Program” (SASEP) modules. https://t.co/71QLhc08xu #gyncsm |
| Dee Sparacio @womenofteal Dee here! Diagnosed Stage3B #ovca 2005, recurrence 2008, OC research advocate, blogger & co-moderator #gyncsm |
 | Inspire @InspireIsHealth RT @gyncsm: We are so pleased to have Kim @KDRichardson924 along with Ben, Tova and Casey from @UICMSTP joining us to discuss the newly released "Survivors Advising Scientists Educational Program” (SASEP) modules. https://t.co/71QLhc08xu #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: We are so pleased to have Kim @KDRichardson924 along with Ben, Tova and Casey from @UICMSTP joining us to discuss the newly released "Survivors Advising Scientists Educational Program” (SASEP) modules. https://t.co/71QLhc08xu #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm One part of this SASEP program addresses understanding scientific posters and we’ll take a look at two from the recent #ASCO20 meeting. #gyncsm |
 | Tobey @BRCAinfo Hi #gyncsm always happy to come & support the chat & learn something new. How is everyone? |
 | Christina Lizaso @btrfly12 Christina Lizaso – passionate re: community engagement and cancer care. I’ll be moderating as @gyncsm today. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: One part of this SASEP program addresses understanding scientific posters and we’ll take a look at two from the recent #ASCO20 meeting. #gyncsm |
 | Alexa Jett 🦋 @ohhiialexa Hey #GYNCSM! I’m Alexa, thyroid cancer survivor and AYA (Adolescent/Young Adult) cancer advocate. I’m a HUGE fan @KDRichardson924 and the work she’s done on this project, so I had to be here!! Been looking forward to it all week. |
 | Rie Lopez, MPH (she/her) @RieOfLetters For the next hour, I will participate in the #gyncsm chat. "we will discuss gynecologic cancer research presented at this year's SGO and virtual ASCO meetings as well as learn about How to Read Scientific Posters". Please join if able. #MedTwitter #scicomm |
| Christina Lizaso @btrfly12 @KDRichardson924 @gyncsm don't forget the hashtag #gyncsm :) |
| Dee Sparacio @womenofteal @BRCAinfo Happy you could be with us tonight! #gyncsm |
| Dee Sparacio @womenofteal @ohhiialexa @KDRichardson924 Hi Alexa So glad you could join us again. #gyncsm |
| Christina Lizaso @btrfly12 @BRCAinfo Hi Tobey! Hanging in there I guess. I'm in Texas. #gyncsm |
| Tobey @BRCAinfo Thanks #gyncsm |
| Dee Sparacio @womenofteal RT @RieOfLetters: For the next hour, I will participate in the #gyncsm chat. "we will discuss gynecologic cancer research presented at this year's SGO and virtual ASCO meetings as well as learn about How to Read Scientific Posters". Please join if able. #MedTwitter #scicomm |
| Alexa Jett 🦋 @ohhiialexa @BRCAinfo Hi, Tobey!! Always good to see you. #GYNCSM |
 | Tanya Temkin @tanyaltee Hi. Tanya from Berkeley here. Eager to help researchers know how to work with OvCa patients as collaborators. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm If you prefer to listen only during the chat, we'd love for you to tweet "#gyncsm" when you join - just to let us know you are here. |
| Inspire @InspireIsHealth @gyncsm Hello to the #gyncsm community, John Novack here from Inspire. |
| Alexa Jett 🦋 @ohhiialexa @womenofteal @KDRichardson924 Thanks so much, Dee! #GYNCSM |
| Tobey @BRCAinfo Hi Christina - I’m in a covid hot zone just like you - Florida #gyncsm |
| Dee Sparacio @womenofteal @tanyaltee Good to see you again ! #gyncsm Thanks for joining us. |
 | Heather 🇺🇸 @ZHeatherChamp Hello fellows! I’m Heather, person w #pten mutation who chose prophylactic hysterectomy in 2013. Got my #previvor status then! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Please continue intro's and welcomes - we'll start in w/ the "ground rules" :) and tips! #gyncsm |
| Dee Sparacio @womenofteal @teaminspire @gyncsm Hi John, Thanks for joining us tonight. #gyncsm |
| Alexa Jett 🦋 @ohhiialexa @ZHeatherChamp Hi Heather!! So good to see you. #GYNCSM |
| GYN Cancer | #GYNCSM @gyncsm The #gyncsm chat promotes community in a public forum. Learn more about risks/benefits: https://t.co/TipZUv1jQy |
| Tobey @BRCAinfo @ohhiialexa Hiya Alexa 🌴nice to see you here too #gyncsm |
 | Michael T. Kennedy @mtkcarraroe RT @gyncsm: We are so pleased to have Kim @KDRichardson924 along with Ben, Tova and Casey from @UICMSTP joining us to discuss the newly released "Survivors Advising Scientists Educational Program” (SASEP) modules. https://t.co/71QLhc08xu #gyncsm |
| Dee Sparacio @womenofteal @BRCAinfo @btrfly12 Totally get it- but seeing some light at the end of the tunnel - NJ resident here. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Are you new to tweet chats? Follow hashtag #gyncsm and include it in every tweet during the next hour to engage with others about this topic. |
| Dee Sparacio @womenofteal @ZHeatherChamp Hi Glad you could stop by tonight! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Please continue intro's and welcomes - we'll start in w/ the "ground rules" :) and tips! #gyncsm |
 | Christine (Cissy) White @healWRITEnow @gyncsm I’m Cissy White. I have the same #ovariancancer my Nana had. I’m a writer & have been a survivor advocate for people with #PTSD from developmental trauma for years. I just signed up for the Suvivors Teaching Students program. Glad to be here #gyncsm |
| Dee Sparacio @womenofteal #gyncsm tagged resources and referrals are not a substitute for speaking with your doctor who understands your needs and history. |
| Alexa Jett 🦋 @ohhiialexa @BRCAinfo I’m in Texas so I feel your hot weather pain! #GYNCSM |
| Dee Sparacio @womenofteal Remember - Twitter is an open social network and posts are public. Use a Direct Messages to exchange email addresses/personal info. #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters Hi everyone! I am Rie. I am a health educator, advocate, enthusiastic researcher, and delightful patient. This community is very dear to me, so I am always glad to be here. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We welcome all those "chiming in" and also all those “listening in”. We'd love you to tweet #gyncsm so we know you are here. You can always tweet, DM or email us with questions/comments after the chat is over. https://t.co/XYaP3OTgsG |
| Dee Sparacio @womenofteal @healWRITEnow @gyncsm So happy to see you tonight! Thanks for joining in - STS is a great program. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: We welcome all those "chiming in" and also all those “listening in”. We'd love you to tweet #gyncsm so we know you are here. You can always tweet, DM or email us with questions/comments after the chat is over. https://t.co/XYaP3OTgsG |
| Dee Sparacio @womenofteal Thank you to all who have tweeted during the past month with the #gyncsm hashtag and those who RT'd about this chat. |
| GYN Cancer | #GYNCSM @gyncsm Tonight, #gyncsm will discuss Gyn Cancer Research and introduce you to the "Survivors Advising Scientists Educational Program” (SASEP) |
| Tanya Temkin @tanyaltee @healWRITEnow @gyncsm Hi cissy! I’ve been with STS for 2 years and love it! #gyncsm |
 | Enlightening Results 💡 @GraceCordovano RT @gyncsm: We welcome all those "chiming in" and also all those “listening in”. We'd love you to tweet #gyncsm so we know you are here. You can always tweet, DM or email us with questions/comments after the chat is over. https://t.co/XYaP3OTgsG |
| GYN Cancer | #GYNCSM @gyncsm Again, we are happy to welcome #ovca advocate Kim @KDRichardson924, creator of "Survivors Advising Scientists Educational Program” and the module presenters/authors, Ben, Tova and Casey tweeting as @UICMSTP #gyncsm |
| Tobey @BRCAinfo @RieOfLetters Hiiiiii. Long time no “see” #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Again, we are happy to welcome #ovca advocate Kim @KDRichardson924, creator of "Survivors Advising Scientists Educational Program” and the module presenters/authors, Ben, Tova and Casey tweeting as @UICMSTP #gyncsm |
 | KD Richardson @KDRichardson924 RT @gyncsm: Again, we are happy to welcome #ovca advocate Kim @KDRichardson924, creator of "Survivors Advising Scientists Educational Program” and the module presenters/authors, Ben, Tova and Casey tweeting as @UICMSTP #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm #gyncsm uses a Topic format with T1; T2 etc. Please include the corresponding T# at the front of your comment or answer. There are 7 Topic Questions for this chat and we’ll wrap up sharing “Today I Learned” (TIL:) thoughts. |
 | UIC MSTP @uicmstp @gyncsm @KDRichardson924 We are so honored to participate in this chat! #gyncsm -BG, TB, and CB |
| Dee Sparacio @womenofteal @gyncsm @KDRichardson924 @uicmstp Feel free to use SASEP when asking or commenting on the program. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm You can find the topic questions we’ll cover on today’s chat on our #gyncsm blog page: https://t.co/GFKS5mDzUW |
| Dee Sparacio @womenofteal @uicmstp @gyncsm @KDRichardson924 And we are thrilled that you are able to take part in this chat. Welcome to the #gyncsm community. |
| Rie Lopez, MPH (she/her) @RieOfLetters @healWRITEnow @gyncsm Nice to meet you Cissy. I also do a lot with mental health advocacy. It is such important work!! Thank you for what you do and I wish you well in the Survivors Teaching Students program. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: You can find the topic questions we’ll cover on today’s chat on our #gyncsm blog page: You can find the topic questions we’ll cover on today’s chat on our #gyncsm blog page: https://t.co/GFKS5mDzUW |
| GYN Cancer | #GYNCSM @gyncsm We are extremely grateful for the healthcare providers who are joining us for this chat. We know your time and energy are precious at all times, but are especially so now. #gyncsm |
 | Janet Freeman-Daily @JFreemanDaily Hi #gyncsm, Janet Freeman-Daily, #lungcancer patient and research advocate, dropping in late. |
 | Amanda Crowell Itliong @MIShouldTalk Hi #gyncsm! It’s Amanda from MI coming to you live from the hospital after another big tumor removal yesterday. |
| Dee Sparacio @womenofteal RT @gyncsm: #gyncsm uses a Topic format with T1; T2 etc. Please include the corresponding T# at the front of your comment or answer. There are 7 Topic Questions for this chat and we’ll wrap up sharing “Today I Learned” (TIL:) thoughts. |
| KD Richardson @KDRichardson924 @gyncsm @uicmstp Thanks for having us! #gyncsm |
| Tobey @BRCAinfo RT @womenofteal: @uicmstp @gyncsm @KDRichardson924 And we are thrilled that you are able to take part in this chat. Welcome to the #gyncsm community. |
| GYN Cancer | #GYNCSM @gyncsm Getting started.... Lots of gyn cancer research has come out so far in 2020. The main two scientific meetings were #SGOMtg and #ASCO2020. @SGO_org is gyn cancer specific and @ASCO covers all cancers. #gyncsm |
| Dee Sparacio @womenofteal @JFreemanDaily Hello! Janet, Glad you could join us #gyncsm |
| Michael T. Kennedy @mtkcarraroe RT @gyncsm: We are extremely grateful for the healthcare providers who are joining us for this chat. We know your time and energy are precious at all times, but are especially so now. #gyncsm |
| Michael T. Kennedy @mtkcarraroe RT @gyncsm: Getting started.... Lots of gyn cancer research has come out so far in 2020. The main two scientific meetings were #SGOMtg and #ASCO2020. @SGO_org is gyn cancer specific and @ASCO covers all cancers. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm You can search the research from these meetings starting at: ASCO 2020 Annual Meeting https://t.co/OEEDQ7UWY0 SGO 2020 Annual Meeting on Women’s Cancer https://t.co/LIDepSiH66 #gyncsm |
| Dee Sparacio @womenofteal @MIShouldTalk Always glad you are here with us Amanda! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Getting started.... Lots of gyn cancer research has come out so far in 2020. The main two scientific meetings were #SGOMtg and #ASCO2020. @SGO_org is gyn cancer specific and @ASCO covers all cancers. #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters @BRCAinfo Hi!!! I am so very glad to "see" you. I have missed you! Must catch up soon. #gyncsm https://t.co/qZuRkrZv4k |
| Christine (Cissy) White @healWRITEnow @RieOfLetters @gyncsm #gyncsm nice to meet you Rie! Thanks for your work as well!! |
| Amanda Crowell Itliong @MIShouldTalk RT @gyncsm: You can search the research from these meetings starting at: ASCO 2020 Annual Meeting https://t.co/OEEDQ7UWY0 SGO 2020 Annual Meeting on Women’s Cancer https://t.co/LIDepSiH66 #gyncsm |
| Michael T. Kennedy @mtkcarraroe RT @gyncsm: You can find the topic questions we’ll cover on today’s chat on our #gyncsm blog page: You can find the topic questions we’ll cover on today’s chat on our #gyncsm blog page: https://t.co/GFKS5mDzUW |
| Dee Sparacio @womenofteal RT @gyncsm: You can search the research from these meetings starting at: ASCO 2020 Annual Meeting https://t.co/OEEDQ7UWY0 SGO 2020 Annual Meeting on Women’s Cancer https://t.co/LIDepSiH66 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Physicians and patient advocates who attend medical meetings often tweet and blog information during the conference to help get the info to more people. The SASEP modules we'll discuss today are helping people feel comfortable accessing and reviewing emerging research. #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @gyncsm: You can search the research from these meetings starting at: ASCO 2020 Annual Meeting https://t.co/OEEDQ7UWY0 SGO 2020 Annual Meeting on Women’s Cancer https://t.co/LIDepSiH66 #gyncsm |
 | Nita Lee @NitaKarnikLee @gyncsm @KDRichardson924 @uicmstp Hello @gyncsm #gyncsm. Excited to learn more details of this program @KDRichardson924 and how we can implement more widely. |
| Dee Sparacio @womenofteal RT @gyncsm: Physicians and patient advocates who attend medical meetings often tweet and blog information during the conference to help get the info to more people. The SASEP modules we'll discuss today are helping people feel comfortable accessing and reviewing emerging research. #gyncsm |
 | Matthew Katz, MD 🟦 @subatomicdoc @womenofteal @JFreemanDaily Good evening! Matt Katz, radiation oncologist - also a little late. Hope you're well 🙂 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We've picked a couple gyn cancer topics to discuss before getting into SASEP and tips on reading a scientific poster using examples from #ASCO2020. #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @gyncsm: Physicians and patient advocates who attend medical meetings often tweet and blog information during the conference to help get the info to more people. The SASEP modules we'll discuss today are helping people feel comfortable accessing and reviewing emerging research. #gyncsm |
| Alexa Jett 🦋 @ohhiialexa RT @gyncsm: Physicians and patient advocates who attend medical meetings often tweet and blog information during the conference to help get the info to more people. The SASEP modules we'll discuss today are helping people feel comfortable accessing and reviewing emerging research. #gyncsm |
| Michael T. Kennedy @mtkcarraroe RT @gyncsm: Physicians and patient advocates who attend medical meetings often tweet and blog information during the conference to help get the info to more people. The SASEP modules we'll discuss today are helping people feel comfortable accessing and reviewing emerging research. #gyncsm |
| Dee Sparacio @womenofteal @NitaKarnikLee @gyncsm @KDRichardson924 @uicmstp Welcome to the #gyncsm community chat. |
| Tobey @BRCAinfo @subatomicdoc @womenofteal @JFreemanDaily 👋 hiya.... I’ve missed you as well. #gyncsm |
| Dee Sparacio @womenofteal @subatomicdoc @JFreemanDaily Hi Matt! Glad you stopped by - Hope you are doing well. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: We've picked a couple gyn cancer topics to discuss before getting into SASEP and tips on reading a scientific poster using examples from #ASCO2020. #gyncsm |
| Michael T. Kennedy @mtkcarraroe RT @gyncsm: You can search the research from these meetings starting at: ASCO 2020 Annual Meeting https://t.co/OEEDQ7UWY0 SGO 2020 Annual Meeting on Women’s Cancer https://t.co/LIDepSiH66 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Here comes Topic 1 (T1:)... Though today we have guests vs. full open discussion - feel free to chime in at any point with comments and questions. #gyncsm |
| Inspire @InspireIsHealth RT @gyncsm: You can search the research from these meetings starting at: ASCO 2020 Annual Meeting https://t.co/OEEDQ7UWY0 SGO 2020 Annual Meeting on Women’s Cancer https://t.co/LIDepSiH66 #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc @BRCAinfo @womenofteal @JFreemanDaily Hi Tobey! Same here, long time no tweet! I hope all is well #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T1: Whether or not a woman should have a second surgery for #ovariancancer continues to be debated. What does the most recent research suggest and what do women need to consider? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Here comes Topic 1 (T1:)... Though today we have guests vs. full open discussion - feel free to chime in at any point with comments and questions. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T1: T1: Whether or not a woman should have a second surgery for #ovariancancer continues to be debated. What does the most recent research suggest and what do women need to consider? #gyncsm |
| KD Richardson @KDRichardson924 @womenofteal @NitaKarnikLee @gyncsm @uicmstp Best partner a patient advocate could ever have! 😊@NitaKarnikLee #gyncsm |
| Alexa Jett 🦋 @ohhiialexa @subatomicdoc @womenofteal @JFreemanDaily It’s a great tweetchat when Dr. Katz shows up!! #GYNCSM |
| Tobey @BRCAinfo @subatomicdoc @womenofteal @JFreemanDaily 👍 thank you. Hoping same for you & yours Dr. Katz #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc @womenofteal @JFreemanDaily Hi Dee! Doing well, just adjusting and keeping the kids and us on an even keel until vacation. How are you? #gyncsm |
| Christina Lizaso @btrfly12 Welcome Christina W - be sure to use the hashtag #gyncsm so all can see your tweets. |
| Tobey @BRCAinfo RT @ohhiialexa: @subatomicdoc @womenofteal @JFreemanDaily It’s a great tweetchat when Dr. Katz shows up!! #GYNCSM |
 | Larissa Nekhlyudov @DrN_CancerPCP @womenofteal @subatomicdoc @JFreemanDaily Hi, DrN here, internist/cancer survivorship physician. Here to listen. #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc @ohhiialexa @womenofteal @JFreemanDaily Thanks so much! You're making me blush ☺️ Good to see you I hope you're well #gyncsm |
| Dee Sparacio @womenofteal T1: Two presentations at #ASCO20 Complete Cytoreductive surgery is crucial in improving outcomes (Desktop III and SOC Studies) Patients with surgery and incomplete resection had worse outcomes (median 28.8 months). https://t.co/S74f8mE14K #gyncsm |
| Inspire @InspireIsHealth RT @womenofteal: T1: T1: Two presentations at #ASCO20 Complete Cytoreductive surgery is crucial in improving outcomes (Desktop III and SOC Studies) Patients with surgery and incomplete resection had worse outcomes (median 28.8 months). https://t.co/S74f8mE14K #gyncsm |
| Dee Sparacio @womenofteal @DrN_CancerPCP @subatomicdoc @JFreemanDaily Hi Dr N Thanks for stopping by. #gyncsm |
| Alexa Jett 🦋 @ohhiialexa @subatomicdoc @womenofteal @JFreemanDaily Of course. You’re an awesome asset to the cancer community, Dr. Katz! #GYNCSM |
| Matthew Katz, MD 🟦 @subatomicdoc @BRCAinfo @womenofteal @JFreemanDaily Yes, all good! And please feel free to call me Matt. I am not that formal a guy. #gyncsm |
| Alexa Jett 🦋 @ohhiialexa RT @womenofteal: T1: T1: Two presentations at #ASCO20 Complete Cytoreductive surgery is crucial in improving outcomes (Desktop III and SOC Studies) Patients with surgery and incomplete resection had worse outcomes (median 28.8 months). https://t.co/S74f8mE14K #gyncsm |
 | Ann Becker-Schutte @DrBeckerSchutte Sorry for late arrival folks—Twitter was not playing nice. #gyncsm |
| Christina Lizaso @btrfly12 Dee was an official @asco social media representative and you can find her recaps on her blog: News from the Virtual #ASCO20 Annual Meeting - Gyn Cancer Highlights https://t.co/f6rpdYId3a #gyncsm |
| Inspire @InspireIsHealth RT @btrfly12: Dee was an official @asco social media representative and you can find her recaps on her blog: News from the Virtual #ASCO20 Annual Meeting - Gyn Cancer Highlights https://t.co/f6rpdYId3a #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc @ohhiialexa @womenofteal @JFreemanDaily Thanks! What I add comes from my listening and learning from you and others. Also, just call me Matt if you want - just another community member with different angle on the same issues #gyncsm |
| Tobey @BRCAinfo @DrBeckerSchutte Omg!!! My day is complete now that u are here. Missssssseeedd YOU #gyncsm |
| Dee Sparacio @womenofteal T1 So basically if complete resection - removing all disease - can be done then women had better outcomes. #gyncsm |
| Dee Sparacio @womenofteal RT @btrfly12: Dee was an official @asco social media representative and you can find her recaps on her blog: News from the Virtual #ASCO20 Annual Meeting - Gyn Cancer Highlights https://t.co/f6rpdYId3a #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters Communicating the latest #research on conditions is often an important part of patient #advocacy. If you do not have a background in #science and/or medicine, it may seem overwhelming. It doesn't have to be. #gyncsm |
| Christina Lizaso @btrfly12 T1: Science builds, but brings up questions for those currently facing treatment and recurrences. But always glad to see gyn cancer studies. #gyncsm |
| Dee Sparacio @womenofteal @DrBeckerSchutte So happy to see you - hope you and your family are well. #gyncsm |
| UIC MSTP @uicmstp RT @RieOfLetters: Communicating the latest #research on conditions is often an important part of patient #advocacy. If you do not have a background in #science and/or medicine, it may seem overwhelming. It doesn't have to be. #gyncsm |
| Alexa Jett 🦋 @ohhiialexa @btrfly12 @ASCO Dee was excellent! I enjoyed her tweets and perspective during #ASCO20. #GYNCSM |
| KD Richardson @KDRichardson924 RT @gyncsm: T1: T1: Whether or not a woman should have a second surgery for #ovariancancer continues to be debated. What does the most recent research suggest and what do women need to consider? #gyncsm |
| Sarah Temkin @temkins Three trials have looked at this question all with slightly different patient enrollment in different environments. To distill the results the decision for secondary cytoreduction for women with #ovariancancer comes down to careful patient selection. #gyncsm https://t.co/MkvWOn2Xfv |
 | Melissa Hicks - 710.9 @710dot9 RT @stales: Have you been treated for #cancer? Please share your thoughts on cancer survivorship care in this anonymous research survey from @UCLAHealth - open to all https://t.co/FYbe0VAQDa #bcsm #lcsm #gyncsm #btsm #ayacsm #mmsm |
| GYN Cancer | #GYNCSM @gyncsm T2: PARP inhibitors took center stage again in the care of women with #ovariancancer. With one study reaching its goal and one that did not, what do women need to know? #gyncsm |
| Tobey @BRCAinfo RT @RieOfLetters: Communicating the latest #research on conditions is often an important part of patient #advocacy. If you do not have a background in #science and/or medicine, it may seem overwhelming. It doesn't have to be. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: We are so pleased to have Kim @KDRichardson924 along with Ben, Tova and Casey from @UICMSTP joining us to discuss the newly released "Survivors Advising Scientists Educational Program” (SASEP) modules. https://t.co/71QLhc08xu #gyncsm |
| Alexa Jett 🦋 @ohhiialexa RT @btrfly12: T1: T1: Science builds, but brings up questions for those currently facing treatment and recurrences. But always glad to see gyn cancer studies. #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @temkins: Three trials have looked at this question all with slightly different patient enrollment in different environments. To distill the results the decision for secondary cytoreduction for women with #ovariancancer comes down to careful patient selection. #gyncsm https://t.co/MkvWOn2Xfv |
| Alexa Jett 🦋 @ohhiialexa RT @RieOfLetters: Communicating the latest #research on conditions is often an important part of patient #advocacy. If you do not have a background in #science and/or medicine, it may seem overwhelming. It doesn't have to be. #gyncsm |
| Dee Sparacio @womenofteal @ohhiialexa @btrfly12 @ASCO NOw you are making me blush ! Thanks so much. #gyncsm |
| Christina Lizaso @btrfly12 RT @RieOfLetters: Communicating the latest #research on conditions is often an important part of patient #advocacy. If you do not have a background in #science and/or medicine, it may seem overwhelming. It doesn't have to be. #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: Three trials have looked at this question all with slightly different patient enrollment in different environments. To distill the results the decision for secondary cytoreduction for women with #ovariancancer comes down to careful patient selection. #gyncsm https://t.co/MkvWOn2Xfv |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: We've picked a couple gyn cancer topics to discuss before getting into SASEP and tips on reading a scientific poster using examples from #ASCO2020. #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @btrfly12: T1: T1: Science builds, but brings up questions for those currently facing treatment and recurrences. But always glad to see gyn cancer studies. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @womenofteal: T1: T1: Two presentations at #ASCO20 Complete Cytoreductive surgery is crucial in improving outcomes (Desktop III and SOC Studies) Patients with surgery and incomplete resection had worse outcomes (median 28.8 months). https://t.co/S74f8mE14K #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @btrfly12: Dee was an official @asco social media representative and you can find her recaps on her blog: News from the Virtual #ASCO20 Annual Meeting - Gyn Cancer Highlights https://t.co/f6rpdYId3a #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T2: T2: PARP inhibitors took center stage again in the care of women with #ovariancancer. With one study reaching its goal and one that did not, what do women need to know? #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @BRCAinfo: @DrBeckerSchutte Omg!!! My day is complete now that u are here. Missssssseeedd YOU #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @womenofteal: T1: T1: Two presentations at #ASCO20 Complete Cytoreductive surgery is crucial in improving outcomes (Desktop III and SOC Studies) Patients with surgery and incomplete resection had worse outcomes (median 28.8 months). https://t.co/S74f8mE14K #gyncsm |
| Christina Lizaso @btrfly12 btw and ICYMI, the #gyncsm community had an online #ASCO2020 abstract: Abstract e14113 Social media and gynecologic cancers: The impact of Twitter https://t.co/3y2sr5dFWX #gyncsm |
| Dee Sparacio @womenofteal T2 The final overall survival (OS) results from SOLO2/ENGOT-ov21 maintenance olaparib study showed an improvement of 12.9 months in median OS vs placebo. #gyncsm |
| Dee Sparacio @womenofteal RT @btrfly12: btw and ICYMI, the #gyncsm community had an online #ASCO2020 abstract: Abstract e14113 Social media and gynecologic cancers: The impact of Twitter https://t.co/3y2sr5dFWX #gyncsm |
| KD Richardson @KDRichardson924 RT @gyncsm: T2: T2: PARP inhibitors took center stage again in the care of women with #ovariancancer. With one study reaching its goal and one that did not, what do women need to know? #gyncsm |
| Christine (Cissy) White @healWRITEnow @womenofteal #gyncsm This Is an interesting study. The overall possible survival benefit is great... unless it’s not. This study leaves me with lots of questions. #gyncsm |
| Tobey @BRCAinfo RT @womenofteal: T2 The final overall survival (OS) results from SOLO2/ENGOT-ov21 maintenance olaparib study showed an improvement of 12.9 months in median OS vs placebo. #gyncsm |
| Sarah Temkin @temkins RT @btrfly12: Dee was an official @asco social media representative and you can find her recaps on her blog: News from the Virtual #ASCO20 Annual Meeting - Gyn Cancer Highlights https://t.co/f6rpdYId3a #gyncsm |
| Alexa Jett 🦋 @ohhiialexa RT @btrfly12: btw and ICYMI, the #gyncsm community had an online #ASCO2020 abstract: Abstract e14113 Social media and gynecologic cancers: The impact of Twitter https://t.co/3y2sr5dFWX #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @btrfly12: btw and ICYMI, the #gyncsm community had an online #ASCO2020 abstract: Abstract e14113 Social media and gynecologic cancers: The impact of Twitter https://t.co/3y2sr5dFWX #gyncsm |
| Christine (Cissy) White @healWRITEnow RT @RieOfLetters: Communicating the latest #research on conditions is often an important part of patient #advocacy. If you do not have a background in #science and/or medicine, it may seem overwhelming. It doesn't have to be. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Program note: We hope you can join the November 8th #gyncsm chat for a full discussion on PARP inhibitors with guest Laura Havrilesky, M.D. who is working on a decision aid for women and reached out to hear from patients. |
| Tobey @BRCAinfo RT @gyncsm: Program note: Program note: We hope you can join the November 8th #gyncsm chat for a full discussion on PARP inhibitors with guest Laura Havrilesky, M.D. who is working on a decision aid for women and reached out to hear from patients. |
| Dee Sparacio @womenofteal 2/2 Cediranib /olaparib demonstrated similar activity to SOC in relapsed platinum -sensitive ovca but did not meet the primary endpoint of improved progression free survival. #gyncsm |
| Dee Sparacio @womenofteal T2 A phase III PARP study compared olaparib to cediranib /olaparib to standard platinum chemo (SOC) in recurrent platinum-sensitive #ovca . 1/2 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T3: What is the "Survivors Advising Scientists Educational Program”? What led to its development? #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @gyncsm: T3: T3: What is the "Survivors Advising Scientists Educational Program”? What led to its development? #gyncsm |
| Tanya Temkin @tanyaltee Improvement in PFS but not OS has long been a sore spot for PARPi’s. This is a groundbreaker. #gyncsm |
| Dee Sparacio @womenofteal @healWRITEnow For me it means if your gyn onc does lots of surgery and can remove all disease - based on how it presents then surgery is a good option . #gyncsm |
| Sarah Temkin @temkins These patients all had germline BRCA mutations and only 38% of the patients receiving placebo went on to receive a parp later. This leaves HUGE questions about the sequencing and timing of parp inhibitors for women with #ovariancancer. #gyncsm. |
| Dee Sparacio @womenofteal RT @gyncsm: Program note: Program note: We hope you can join the November 8th #gyncsm chat for a full discussion on PARP inhibitors with guest Laura Havrilesky, M.D. who is working on a decision aid for women and reached out to hear from patients. |
| GYN Cancer | #GYNCSM @gyncsm #gyncsm : |
| Dee Sparacio @womenofteal RT @gyncsm: T3: T3: What is the "Survivors Advising Scientists Educational Program”? What led to its development? #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @btrfly12: btw and ICYMI, the #gyncsm community had an online #ASCO2020 abstract: Abstract e14113 Social media and gynecologic cancers: The impact of Twitter https://t.co/3y2sr5dFWX #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: These patients all had germline BRCA mutations and only 38% of the patients receiving placebo went on to receive a parp later. This leaves HUGE questions about the sequencing and timing of parp inhibitors for women with #ovariancancer. #gyncsm. |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: Here comes Topic 1 (T1:)... Though today we have guests vs. full open discussion - feel free to chime in at any point with comments and questions. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: T2: T2: PARP inhibitors took center stage again in the care of women with #ovariancancer. With one study reaching its goal and one that did not, what do women need to know? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: #gyncsm : #gyncsm : |
| Christine (Cissy) White @healWRITEnow RT @tanyaltee: Improvement in PFS but not OS has long been a sore spot for PARPi’s. This is a groundbreaker. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @healWRITEnow: @womenofteal #gyncsm This Is an interesting study. The overall possible survival benefit is great... unless it’s not. This study leaves me with lots of questions. #gyncsm |
| Alexa Jett 🦋 @ohhiialexa @uicmstp @gyncsm @uiccom Thank you SO MUCH for coming! I am in awe of the work you all (and @KDRichardson924!! ❤️) are doing. I feel like this is a game changer for patient advocacy. #GYNCSM |
| Dee Sparacio @womenofteal RT @ohhiialexa: @uicmstp @gyncsm @uiccom Thank you SO MUCH for coming! I am in awe of the work you all (and @KDRichardson924!! ❤️) are doing. I feel like this is a game changer for patient advocacy. #GYNCSM |
| UIC MSTP @uicmstp Thanks again for having us… we are so honored! Also, thank you to @KDRichardson924 for her tremendous leadership/mentorship #gyncsm -BG,TB,CB |
| Tobey @BRCAinfo RT @ohhiialexa: @uicmstp @gyncsm @uiccom Thank you SO MUCH for coming! I am in awe of the work you all (and @KDRichardson924!! ❤️) are doing. I feel like this is a game changer for patient advocacy. #GYNCSM |
| Dee Sparacio @womenofteal RT @uicmstp: Thanks again for having us… we are so honored! Also, thank you to @KDRichardson924 for her tremendous leadership/mentorship #gyncsm -BG,TB,CB |
| KD Richardson @KDRichardson924 RT @uicmstp: Thanks again for having us… we are so honored! Also, thank you to @KDRichardson924 for her tremendous leadership/mentorship #gyncsm -BG,TB,CB |
| Rie Lopez, MPH (she/her) @RieOfLetters @healWRITEnow @womenofteal Yes! I pulled up the abstract, just to get an overview until I have more time. Interesting point where it appears that no surgery has a better mortality rate than an incomplete resection (46.2 vs 28.8 mos). Lots to unpack in the full study! #gyncsm |
| Dee Sparacio @womenofteal RT @RieOfLetters: @healWRITEnow @womenofteal Yes! I pulled up the abstract, just to get an overview until I have more time. Interesting point where it appears that no surgery has a better mortality rate than an incomplete resection (46.2 vs 28.8 mos). Lots to unpack in the full study! #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @btrfly12: btw and ICYMI, the #gyncsm community had an online #ASCO2020 abstract: Abstract e14113 Social media and gynecologic cancers: The impact of Twitter https://t.co/3y2sr5dFWX #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T3: What is the "Survivors Advising Scientists Educational Program”? What led to its development? T4: What topics do the SASEP modules cover? Where can patients go to learn more about the program? #gyncsm |
| Dee Sparacio @womenofteal @KDRichardson924 T3: What is the "Survivors Advising Scientists Educational Program”? What led to its development? #GYNCSM |
| Matthew Katz, MD 🟦 @subatomicdoc RT @tanyaltee: Improvement in PFS but not OS has long been a sore spot for PARPi’s. This is a groundbreaker. #gyncsm |
| Heather 🇺🇸 @ZHeatherChamp RT @gyncsm: T3: T3: What is the "Survivors Advising Scientists Educational Program”? What led to its development? #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm @KDRichardson924: Survivors Advising Scientists is a program initiative I developed while participating in NCCS ELEVATE Ambassador Program last year. #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @gyncsm: T3: T3: What is the "Survivors Advising Scientists Educational Program”? What led to its development? T4: What topics do the SASEP modules cover? Where can patients go to learn more about the program? #gyncsm |
| Dee Sparacio @womenofteal #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: @KDRichardson924: Survivors Advising Scientists is a program initiative I developed while participating in NCCS ELEVATE Ambassador Program last year. #gyncsm |
| Dee Sparacio @womenofteal @healWRITEnow Scans - MRI/CT/PET can show discrete lesions that may be removed . If the presentation is speckled (can't think of the med term) then surgery would be very difficult. #gyncsm |
| UIC MSTP @uicmstp T4: The topics are designed to introduce important scientific concepts so cancer research advocates and patients can participate in scientific dialogue and important decision making. The modules cover the following: #gyncsm (1/3) -BG/CB |
| Dee Sparacio @womenofteal T4: What topics do the SASEP modules cover? Where can patients go to learn more about the program? #gyncsm |
| Alexa Jett 🦋 @ohhiialexa @KDRichardson924 took being an @CancerAdvocacy ELEVATE Ambassador to an incredible place. I consider Kimberly a role model for younger advocates like myself and has proved “the power of one”! #GYNCSM |
| Dee Sparacio @womenofteal RT @uicmstp: T4: T4: The topics are designed to introduce important scientific concepts so cancer research advocates and patients can participate in scientific dialogue and important decision making. The modules cover the following: #gyncsm (1/3) -BG/CB |
| UIC MSTP @uicmstp T4 (2/3) 1.Scientific Hypotheses 2.Components of a Hypothesis 3.Exp. Variables 4.Confounding Variables 5. Exp. Errors 6.Stat Significance 7.Types of Clinical Studies https://t.co/2qkEuex0bN Bias and Randomization https://t.co/Rw3wiLuPE1 to Read Scientific Poster #gyncsm - BG/CB |
| Alexa Jett 🦋 @ohhiialexa RT @uicmstp: T4: T4: The topics are designed to introduce important scientific concepts so cancer research advocates and patients can participate in scientific dialogue and important decision making. The modules cover the following: #gyncsm (1/3) -BG/CB |
| UIC MSTP @uicmstp T4 (3/3) Additionally, we are currently looking for more content ideas. Please email us at SASEP@UIC.edu for any suggestions. You can access the videos here: https://t.co/nvNz75G5Ht #gyncsm - BG/CB |
| Dee Sparacio @womenofteal @ohhiialexa @KDRichardson924 @CancerAdvocacy Agree 100%! #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @uicmstp: T4: T4: The topics are designed to introduce important scientific concepts so cancer research advocates and patients can participate in scientific dialogue and important decision making. The modules cover the following: #gyncsm (1/3) -BG/CB |
| Dee Sparacio @womenofteal RT @uicmstp: T4 (2/3) 1.Scientific Hypotheses 2.Components of a Hypothesis 3.Exp. Variables 4.Confounding Variables 5. Exp. Errors 6.Stat Significance 7.Types of Clinical Studies https://t.co/2qkEuex0bN Bias and Randomization https://t.co/Rw3wiLuPE1 to Read Scientific Poster #gyncsm - BG/CB |
| Matthew Katz, MD 🟦 @subatomicdoc RT @uicmstp: T4 (2/3) 1.Scientific Hypotheses 2.Components of a Hypothesis 3.Exp. Variables 4.Confounding Variables 5. Exp. Errors 6.Stat Significance 7.Types of Clinical Studies https://t.co/2qkEuex0bN Bias and Randomization https://t.co/Rw3wiLuPE1 to Read Scientific Poster #gyncsm - BG/CB |
| Dee Sparacio @womenofteal RT @uicmstp: T4 (3/3) Additionally, we are currently looking for more content ideas. Please email us at SASEP@UIC.edu for any suggestions. You can access the videos here: https://t.co/nvNz75G5Ht #gyncsm - BG/CB |
| Alexa Jett 🦋 @ohhiialexa RT @uicmstp: T4 (3/3) Additionally, we are currently looking for more content ideas. Please email us at SASEP@UIC.edu for any suggestions. You can access the videos here: https://t.co/nvNz75G5Ht #gyncsm - BG/CB |
| Tobey @BRCAinfo RT @uicmstp: T4 (3/3) Additionally, we are currently looking for more content ideas. Please email us at SASEP@UIC.edu for any suggestions. You can access the videos here: https://t.co/nvNz75G5Ht #gyncsm - BG/CB |
| GYN Cancer | #GYNCSM @gyncsm T5: Let’s talk about the module on “How to Read a Scientific Poster”. What are the main points patients/advocates should consider when reading a scientific poster presented at an annual meeting like ASCO or SGO? #gyncsm |
| Christine (Cissy) White @healWRITEnow @womenofteal I don’t know med term either. My surgeon describes it as “rice-like” #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T5: T5: Let’s talk about the module on “How to Read a Scientific Poster”. What are the main points patients/advocates should consider when reading a scientific poster presented at an annual meeting like ASCO or SGO? #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @uicmstp: T4 (3/3) Additionally, we are currently looking for more content ideas. Please email us at SASEP@UIC.edu for any suggestions. You can access the videos here: https://t.co/nvNz75G5Ht #gyncsm - BG/CB |
| UIC MSTP @uicmstp T5 the direction in which sci. posters r typically read is from top to bottom, left to right. Some conferences will have requirements that all research presenters must follow. For ASCO’s conference, all main findings must be placed in the middle of poster. #gyncsm (1/4) BG/CB |
| Matthew Katz, MD 🟦 @subatomicdoc RT @gyncsm: T5: T5: Let’s talk about the module on “How to Read a Scientific Poster”. What are the main points patients/advocates should consider when reading a scientific poster presented at an annual meeting like ASCO or SGO? #gyncsm |
| Christina Lizaso @btrfly12 RT @uicmstp: T4: T4: The topics are designed to introduce important scientific concepts so cancer research advocates and patients can participate in scientific dialogue and important decision making. The modules cover the following: #gyncsm (1/3) -BG/CB |
| UIC MSTP @uicmstp T5 (2/4) The next and one of the most important pieces of a poster is the hypothesis which is usually found in the top left corner. The hypothesis is the an educated guess the researchers use to try to answer a scientific question. #gyncsm BG/CB |
| Rie Lopez, MPH (she/her) @RieOfLetters Notable thread following up to discussion on a SOLO2/ENGOT-ov21 maintenance olaparib study (discussed by @womenofteal). #research #medtwitter #gynscm |
| Christina Lizaso @btrfly12 RT @uicmstp: T4 (2/3) 1.Scientific Hypotheses 2.Components of a Hypothesis 3.Exp. Variables 4.Confounding Variables 5. Exp. Errors 6.Stat Significance 7.Types of Clinical Studies https://t.co/2qkEuex0bN Bias and Randomization https://t.co/Rw3wiLuPE1 to Read Scientific Poster #gyncsm - BG/CB |
| UIC MSTP @uicmstp T5 (3/4) Some of the more interesting parts of a poster are the results or data, which are usually found in the center column/s of a poster. This section shows readers what information the researchers gathered/learned as a result of their experiments. #gyncsm BG/CB |
| Christina Lizaso @btrfly12 RT @uicmstp: T4 (3/3) Additionally, we are currently looking for more content ideas. Please email us at SASEP@UIC.edu for any suggestions. You can access the videos here: https://t.co/nvNz75G5Ht #gyncsm - BG/CB |
| UIC MSTP @uicmstp T5 (4/4) If you’re overwhelmed reading a poster, another good place to look is the conclusions section, usually found in the bottom right corner (for ASCO, in the center column). This area summarizes the results of the study and may point out what is left to do. #gyncsm BG/CB |
| Alexa Jett 🦋 @ohhiialexa @healWRITEnow @womenofteal Ohhh, I like this! That’s a great way to easily explain it. #GYNCSM |
| Dee Sparacio @womenofteal RT @uicmstp: T5 (2/4) The next and one of the most important pieces of a poster is the hypothesis which is usually found in the top left corner. The hypothesis is the an educated guess the researchers use to try to answer a scientific question. #gyncsm BG/CB |
| Tanya Temkin @tanyaltee Will have to open, bookmark, and go through this carefully. Not while multitasking on a Twitter chat. #gyncsm |
| Alexa Jett 🦋 @ohhiialexa RT @uicmstp: T5 (2/4) The next and one of the most important pieces of a poster is the hypothesis which is usually found in the top left corner. The hypothesis is the an educated guess the researchers use to try to answer a scientific question. #gyncsm BG/CB |
| Dee Sparacio @womenofteal RT @uicmstp: T5 (3/4) Some of the more interesting parts of a poster are the results or data, which are usually found in the center column/s of a poster. This section shows readers what information the researchers gathered/learned as a result of their experiments. #gyncsm BG/CB |
| Christine (Cissy) White @healWRITEnow @temkins @womenofteal I had to look that word up. Got it now! #gyncsm |
| Alexa Jett 🦋 @ohhiialexa RT @uicmstp: T5 (4/4) If you’re overwhelmed reading a poster, another good place to look is the conclusions section, usually found in the bottom right corner (for ASCO, in the center column). This area summarizes the results of the study and may point out what is left to do. #gyncsm BG/CB |
| Dee Sparacio @womenofteal RT @uicmstp: T5 (4/4) If you’re overwhelmed reading a poster, another good place to look is the conclusions section, usually found in the bottom right corner (for ASCO, in the center column). This area summarizes the results of the study and may point out what is left to do. #gyncsm BG/CB |
| GYN Cancer | #GYNCSM @gyncsm RT @uicmstp: T5 the direction in which sci. posters r typically read is from top to bottom, left to right. Some conferences will have requirements that all research presenters must follow. For ASCO’s conference, all main findings must be placed in the middle of poster. #gyncsm (1/4) BG/CB |
| Tobey @BRCAinfo @uicmstp This is where I go first ~ wonderful advice #gyncsm |
| Tobey @BRCAinfo RT @uicmstp: T5 (4/4) If you’re overwhelmed reading a poster, another good place to look is the conclusions section, usually found in the bottom right corner (for ASCO, in the center column). This area summarizes the results of the study and may point out what is left to do. #gyncsm BG/CB |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: T5: T5: Let’s talk about the module on “How to Read a Scientific Poster”. What are the main points patients/advocates should consider when reading a scientific poster presented at an annual meeting like ASCO or SGO? #gyncsm |
| Alexa Jett 🦋 @ohhiialexa @BRCAinfo @uicmstp Sometimes reading the conclusion first helps me understand the research better! #GYNCSM |
| GYN Cancer | #GYNCSM @gyncsm T6: This poster from #ASCO2020 reports on the low rate of BRCA testing for patients with #ovariancancer. Using this as an example can you walk us through how an advocate/patient/survivor could read and understand it? #gyncsm https://t.co/UnuQDpMPUB |
| Dee Sparacio @womenofteal RT @ohhiialexa: @BRCAinfo @uicmstp Sometimes reading the conclusion first helps me understand the research better! #GYNCSM |
| Sarah Temkin @temkins RT @uicmstp: T5 (4/4) If you’re overwhelmed reading a poster, another good place to look is the conclusions section, usually found in the bottom right corner (for ASCO, in the center column). This area summarizes the results of the study and may point out what is left to do. #gyncsm BG/CB |
| UIC MSTP @uicmstp @tanyaltee Thank you for your response. Please take your time! =] The modules are ~10 minutes each (and there are 9 of them), so it is definitely a smart idea to bookmark and check them out later when it is convenient. -BG #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T6: T6: This poster from #ASCO2020 reports on the low rate of BRCA testing for patients with #ovariancancer. Using this as an example can you walk us through how an advocate/patient/survivor could read and understand it? #gyncsm https://t.co/UnuQDpMPUB |
| UIC MSTP @uicmstp T6 Some posters may be intimidating with jargon and lots of numbers/data. But following simple steps can help break concepts down so you can begin to understand the “big picture” of the study. #gyncsm (1/9) -TB (entire thread) |
| UIC MSTP @uicmstp T6 (2/9) Title: the title of this poster makes it clear the topic is about the low rate of testing for BRCA1/2 mutations in ovarian cancer patients, but we need to read a little more to get more information. #gyncsm |
| Sarah Temkin @temkins @gyncsm We have an implementation problem in getting #genetictesting for women with ovariancaner @sdewdney #gyncsm. |
| Tanya Temkin @tanyaltee @healWRITEnow @temkins @womenofteal I was crushed that I couldn’t get primary surgery because peritoneal carcinomatosis. Had to go interval after neoadjuvant tx. #gyncsm |
| UIC MSTP @uicmstp T6 (3/9) In this poster, the next big section that catches your eye is the paragraph in the center. You would most likely read this summary first to get the “take home” message, then continue to read the poster normally. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T6 Some posters may be intimidating with jargon and lots of numbers/data. But following simple steps can help break concepts down so you can begin to understand the “big picture” of the study. #gyncsm (1/9) -TB (entire thread) |
| UIC MSTP @uicmstp T6 (4/9) Background: this section gives a brief introduction to ovarian cancer and the two genes of interest. Here we learn these genes increase the risk of likelihood of developing ovarian cancer. #ovca #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T6 (2/9) Title: T6 (2/9) Title: the title of this poster makes it clear the topic is about the low rate of testing for BRCA1/2 mutations in ovarian cancer patients, but we need to read a little more to get more information. #gyncsm |
| UIC MSTP @uicmstp T6 (5/9) Methods: this section has a flow chart explaining the process of data collection. This is not the most important part if you’re reading to find results, but it can provide a lot of information about how well the study was designed. #gyncsm |
| Christina Lizaso @btrfly12 RT @temkins: @gyncsm We have an implementation problem in getting #genetictesting for women with ovariancaner @sdewdney #gyncsm. |
| UIC MSTP @uicmstp T6 (6/9) Method 2: You’ll also see a demographics table on the far right of the poster. This information could be considered part of the methods, since it is describing the body of patients included in the study. #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @gyncsm: T6: T6: This poster from #ASCO2020 reports on the low rate of BRCA testing for patients with #ovariancancer. Using this as an example can you walk us through how an advocate/patient/survivor could read and understand it? #gyncsm https://t.co/UnuQDpMPUB |
| Inspire @InspireIsHealth RT @gyncsm: T6: T6: This poster from #ASCO2020 reports on the low rate of BRCA testing for patients with #ovariancancer. Using this as an example can you walk us through how an advocate/patient/survivor could read and understand it? #gyncsm https://t.co/UnuQDpMPUB |
| UIC MSTP @uicmstp T6 (7/9) Results: this section is in the bottom left - which is a little unusual but looks like it was done for spacing purposes. There is also a large results box in the middle of the poster - designed to draw attention to the “take home” message quickly. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T6 (3/9) In this poster, the next big section that catches your eye is the paragraph in the center. You would most likely read this summary first to get the “take home” message, then continue to read the poster normally. #gyncsm |
| UIC MSTP @uicmstp T6 (8/9) Discussion: this section is describing the results or conclusions of the research. This is also sometimes called “conclusions”, but it is very important because it shares results and puts them into context. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T6 (4/9) Background: T6 (4/9) Background: this section gives a brief introduction to ovarian cancer and the two genes of interest. Here we learn these genes increase the risk of likelihood of developing ovarian cancer. #ovca #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T6 (5/9) Methods: T6 (5/9) Methods: this section has a flow chart explaining the process of data collection. This is not the most important part if you’re reading to find results, but it can provide a lot of information about how well the study was designed. #gyncsm |
| UIC MSTP @uicmstp T6 (9/9) Discussion 2: This poster shows that only a very small percentage of patients with ovarian cancer had a documented test for BRCA1/2 mutation, even though guidance suggests that all patients should receive this test. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: T6: T6: This poster from #ASCO2020 reports on the low rate of BRCA testing for patients with #ovariancancer. Using this as an example can you walk us through how an advocate/patient/survivor could read and understand it? #gyncsm https://t.co/UnuQDpMPUB |
| Dee Sparacio @womenofteal RT @uicmstp: T6 (6/9) Method 2: T6 (6/9) Method 2: You’ll also see a demographics table on the far right of the poster. This information could be considered part of the methods, since it is describing the body of patients included in the study. #gyncsm |
| Alexa Jett 🦋 @ohhiialexa RT @uicmstp: T6 (8/9) Discussion: T6 (8/9) Discussion: this section is describing the results or conclusions of the research. This is also sometimes called “conclusions”, but it is very important because it shares results and puts them into context. #gyncsm |
| Alexa Jett 🦋 @ohhiialexa RT @uicmstp: T6 (9/9) Discussion 2: T6 (9/9) Discussion 2: This poster shows that only a very small percentage of patients with ovarian cancer had a documented test for BRCA1/2 mutation, even though guidance suggests that all patients should receive this test. #gyncsm |
| Christina Lizaso @btrfly12 RT @uicmstp: T6 (9/9) Discussion 2: T6 (9/9) Discussion 2: This poster shows that only a very small percentage of patients with ovarian cancer had a documented test for BRCA1/2 mutation, even though guidance suggests that all patients should receive this test. #gyncsm |
| KD Richardson @KDRichardson924 RT @uicmstp: T4 (3/3) Additionally, we are currently looking for more content ideas. Please email us at SASEP@UIC.edu for any suggestions. You can access the videos here: https://t.co/nvNz75G5Ht #gyncsm - BG/CB |
| Dee Sparacio @womenofteal @temkins @gyncsm @sdewdney Yes - I hope the @ASCO guidelines will help implement more testing #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters Essential #science process, organized into modules. Each build upon each other, resulting in the knowledge that will allow you to read and understand a scientific poster. This is also useful for understanding published #research. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T6 (7/9) Results: T6 (7/9) Results: this section is in the bottom left - which is a little unusual but looks like it was done for spacing purposes. There is also a large results box in the middle of the poster - designed to draw attention to the “take home” message quickly. #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @RieOfLetters: Essential #science process, organized into modules. Each build upon each other, resulting in the knowledge that will allow you to read and understand a scientific poster. This is also useful for understanding published #research. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T6 (8/9) Discussion: T6 (8/9) Discussion: this section is describing the results or conclusions of the research. This is also sometimes called “conclusions”, but it is very important because it shares results and puts them into context. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T6 (9/9) Discussion 2: T6 (9/9) Discussion 2: This poster shows that only a very small percentage of patients with ovarian cancer had a documented test for BRCA1/2 mutation, even though guidance suggests that all patients should receive this test. #gyncsm |
| KD Richardson @KDRichardson924 RT @gyncsm: T6: T6: This poster from #ASCO2020 reports on the low rate of BRCA testing for patients with #ovariancancer. Using this as an example can you walk us through how an advocate/patient/survivor could read and understand it? #gyncsm https://t.co/UnuQDpMPUB |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @uicmstp: T5 the direction in which sci. posters r typically read is from top to bottom, left to right. Some conferences will have requirements that all research presenters must follow. For ASCO’s conference, all main findings must be placed in the middle of poster. #gyncsm (1/4) BG/CB |
| Rie Lopez, MPH (she/her) @RieOfLetters RT @uicmstp: T5 (2/4) The next and one of the most important pieces of a poster is the hypothesis which is usually found in the top left corner. The hypothesis is the an educated guess the researchers use to try to answer a scientific question. #gyncsm BG/CB |
| GYN Cancer | #GYNCSM @gyncsm T7: Here is another poster from #ASCO2020 discussing early-line treatment for #endometrialcancer. Using the tips from your module, what are the key points to learn from this poster? #gyncsm https://t.co/5pxRFlSXG6 |
| Dee Sparacio @womenofteal @RieOfLetters Having gotten a peak at these modules before release they really are excellent. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T7: T7: Here is another poster from #ASCO2020 discussing early-line treatment for #endometrialcancer. Using the tips from your module, what are the key points to learn from this poster? #gyncsm https://t.co/5pxRFlSXG6 |
| Christina Lizaso @btrfly12 RT @RieOfLetters: Essential #science process, organized into modules. Each build upon each other, resulting in the knowledge that will allow you to read and understand a scientific poster. This is also useful for understanding published #research. #gyncsm |
| UIC MSTP @uicmstp RT @womenofteal: @RieOfLetters Having gotten a peak at these modules before release they really are excellent. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: T7: T7: Here is another poster from #ASCO2020 discussing early-line treatment for #endometrialcancer. Using the tips from your module, what are the key points to learn from this poster? #gyncsm https://t.co/5pxRFlSXG6 |
| UIC MSTP @uicmstp T7 Title tells us that a drug combination (Lenvatinib + Pembrolizumab) is being tested as early treatment for endometrial cancer. If these therapies r unfamiliar to you, you can ask the presenter for more information or look them up on google scholar or pubmed. #gyncsm (1/9)TB |
| UIC MSTP @uicmstp T7 (2/9) The goal of the study is to evaluate the safety and efficacy of this drug combination. They use the word “post hoc” analysis, which means the clinical trial has already been performed and now they are analyzing the data. #gyncsm |
| UIC MSTP @uicmstp T7 (3/9) Post-hoc means they are not stating a hypothesis as they would if they were currently designing the clinical trial (eg, combination therapy will lead to increased overall survival compared to standard chemotherapy in patients with endometrial cancer). #gyncsm |
| KD Richardson @KDRichardson924 RT @gyncsm: T7: T7: Here is another poster from #ASCO2020 discussing early-line treatment for #endometrialcancer. Using the tips from your module, what are the key points to learn from this poster? #gyncsm https://t.co/5pxRFlSXG6 |
| UIC MSTP @uicmstp T7 (4/9) Methods: Here we see the researchers are analyzing data from KEYNOTE clinical trial (NCT02501096). The “overall population” is the larger group of patients with endometrial cancer. Subgroup 1 is small subset of those patients who haven’t received much treatment #gyncsm |
| UIC MSTP @uicmstp T7 (5/9) Methods 2: This study is using post-hoc (after trial completion) analysis to compare the effect of the treatment in subgroup 1 and the overall population to determine if it would work as an early-line treatment. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @RieOfLetters: Essential #science process, organized into modules. Each build upon each other, resulting in the knowledge that will allow you to read and understand a scientific poster. This is also useful for understanding published #research. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T7 Title tells us that a drug combination (Lenvatinib + Pembrolizumab) is being tested as early treatment for endometrial cancer. If these therapies r unfamiliar to you, you can ask the presenter for more information or look them up on google scholar or pubmed. #gyncsm (1/9)TB |
| Dee Sparacio @womenofteal RT @uicmstp: T7 (2/9) The goal of the study is to evaluate the safety and efficacy of this drug combination. They use the word “post hoc” analysis, which means the clinical trial has already been performed and now they are analyzing the data. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T7 (3/9) Post-hoc means they are not stating a hypothesis as they would if they were currently designing the clinical trial (eg, combination therapy will lead to increased overall survival compared to standard chemotherapy in patients with endometrial cancer). #gyncsm |
| KD Richardson @KDRichardson924 RT @RieOfLetters: Essential #science process, organized into modules. Each build upon each other, resulting in the knowledge that will allow you to read and understand a scientific poster. This is also useful for understanding published #research. #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters Hands down, my favorite part of scientific posters. Then again, I was always a fan of the details. If you want a quick overview, the conclusion is the place to go. It keeps you from getting bogged down in the details. #research #science #gyncsm |
| UIC MSTP @uicmstp T7 (6/9) Results: Efficacy is the key word for this poster (bottom left corner) - did the drug combination being tested work? U can see that 36% of the overall population had a response to the treatment - or the treatment worked to improve disease state in 36% of patients #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T7 (4/9) Methods: T7 (4/9) Methods: Here we see the researchers are analyzing data from KEYNOTE clinical trial (NCT02501096). The “overall population” is the larger group of patients with endometrial cancer. Subgroup 1 is small subset of those patients who haven’t received much treatment #gyncsm |
| Tanya Temkin @tanyaltee Also need more referrals for genetic testing *before* women develop #ovariancancer so they can take preventive steps!! #gyncsm |
| UIC MSTP @uicmstp T7 (7/9) Safety: Since this poster is about a clinical trial, this section is important to include information for both clinicians and patients. The safety profile of the subgroup population matches the overall population and no new safety concerns were found. #gyncsm |
| UIC MSTP @uicmstp T7 (8/9) Conclusions: The conclusions are found right in the middle in large font - designed so that they are easy to find. #gyncsm |
| UIC MSTP @uicmstp T7 (9/9) Conclusions 2: The conclusion is that the treatment (lenvatinib + pembrolizumab) seems to work in this study for this population (advanced endometrial cancer that is not MSI-H or dMMR) as a method of early-line treatment. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Well that moved fast! Special thanks to our guests. You are official twitter guest rockstars now. As we finish up the hour, please share any closing thoughts on our topic. If you like, you can start your tweet with TIL: for Today I Learned. #gyncsm |
| Christine (Cissy) White @healWRITEnow RT @tanyaltee: Also need more referrals for genetic testing *before* women develop #ovariancancer so they can take preventive steps!! #gyncsm |
| KD Richardson @KDRichardson924 RT @RieOfLetters: Communicating the latest #research on conditions is often an important part of patient #advocacy. If you do not have a background in #science and/or medicine, it may seem overwhelming. It doesn't have to be. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T7 (6/9) Results: T7 (6/9) Results: Efficacy is the key word for this poster (bottom left corner) - did the drug combination being tested work? U can see that 36% of the overall population had a response to the treatment - or the treatment worked to improve disease state in 36% of patients #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T7 (5/9) Methods 2: T7 (5/9) Methods 2: This study is using post-hoc (after trial completion) analysis to compare the effect of the treatment in subgroup 1 and the overall population to determine if it would work as an early-line treatment. #gyncsm |
| UIC MSTP @uicmstp @RieOfLetters agreed! -BG #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T7 (7/9) Safety: T7 (7/9) Safety: Since this poster is about a clinical trial, this section is important to include information for both clinicians and patients. The safety profile of the subgroup population matches the overall population and no new safety concerns were found. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Note that in the coming months, we’ll have the chance to discuss more gyn cancer research as we chat about endometrial cancer (Aug 12) and rare ovarian cancers (Sept 9). #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T7 (8/9) Conclusions: T7 (8/9) Conclusions: The conclusions are found right in the middle in large font - designed so that they are easy to find. #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: T7 (9/9) Conclusions 2: T7 (9/9) Conclusions 2: The conclusion is that the treatment (lenvatinib + pembrolizumab) seems to work in this study for this population (advanced endometrial cancer that is not MSI-H or dMMR) as a method of early-line treatment. #gyncsm |
| UIC MSTP @uicmstp RT @gyncsm: Well that moved fast! Special thanks to our guests. You are official twitter guest rockstars now. As we finish up the hour, please share any closing thoughts on our topic. If you like, you can start your tweet with TIL: for Today I Learned. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Well that moved fast! Special thanks to our guests. You are official twitter guest rockstars now. As we finish up the hour, please share any closing thoughts on our topic. If you like, you can start your tweet with TIL: for Today I Learned. #gyncsm |
| UIC MSTP @uicmstp And 26% of patients in subgroup 1 responded #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Note that in the coming months, we’ll have the chance to discuss more gyn cancer research as we chat about endometrial cancer (Aug 12) and rare ovarian cancers (Sept 9). #gyncsm |
| Dee Sparacio @womenofteal RT @uicmstp: And 26% of patients in subgroup 1 responded #gyncsm |
| UIC MSTP @uicmstp We really appreciate the platform. SASEP would not be possible without @KDRichardson924 ! Please feel free to email feedback re SASEP modules/ content ideas at SASEP@uic.edu #gyncsm -BG,TB,CB |
| Alexa Jett 🦋 @ohhiialexa TIL: That there are many people out there making advocacy better. I fully and truly believe that patient advocates belong in the scientific space. Education is the key here, and I’m thrilled with these modules. #GYNCSM |
| Tobey @BRCAinfo @gyncsm As always Tysvm #gyncsm for all you do. Please stay safe & well. Hope to “see” you all again next month 🙏☺️ |
| Alexa Jett 🦋 @ohhiialexa RT @uicmstp: We really appreciate the platform. SASEP would not be possible without @KDRichardson924 ! Please feel free to email feedback re SASEP modules/ content ideas at SASEP@uic.edu #gyncsm -BG,TB,CB |
| Dee Sparacio @womenofteal RT @uicmstp: We really appreciate the platform. SASEP would not be possible without @KDRichardson924 ! Please feel free to email feedback re SASEP modules/ content ideas at SASEP@uic.edu #gyncsm -BG,TB,CB |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: Well that moved fast! Special thanks to our guests. You are official twitter guest rockstars now. As we finish up the hour, please share any closing thoughts on our topic. If you like, you can start your tweet with TIL: for Today I Learned. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm So thankful for our guests from the "Survivors Advising Scientists Educational Program” Kim @KDRichardson924 and Ben, Tova and Casey tweeting as @UICMSTP Learn more here: https://t.co/gypjlp7s0r #gyncsm |
| Dee Sparacio @womenofteal RT @ohhiialexa: TIL: TIL: That there are many people out there making advocacy better. I fully and truly believe that patient advocates belong in the scientific space. Education is the key here, and I’m thrilled with these modules. #GYNCSM |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: So thankful for our guests from the "Survivors Advising Scientists Educational Program” Kim @KDRichardson924 and Ben, Tova and Casey tweeting as @UICMSTP Learn more here: https://t.co/gypjlp7s0r #gyncsm |
| KD Richardson @KDRichardson924 RT @gyncsm: So thankful for our guests from the "Survivors Advising Scientists Educational Program” Kim @KDRichardson924 and Ben, Tova and Casey tweeting as @UICMSTP Learn more here: https://t.co/gypjlp7s0r #gyncsm |
| Tobey @BRCAinfo RT @gyncsm: So thankful for our guests from the "Survivors Advising Scientists Educational Program” Kim @KDRichardson924 and Ben, Tova and Casey tweeting as @UICMSTP Learn more here: https://t.co/gypjlp7s0r #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm As always, remember to tweet things of interest with hashtag #gyncsm to keep the conversation going between chats. |
| Dee Sparacio @womenofteal RT @gyncsm: So thankful for our guests from the "Survivors Advising Scientists Educational Program” Kim @KDRichardson924 and Ben, Tova and Casey tweeting as @UICMSTP Learn more here: https://t.co/gypjlp7s0r #gyncsm |
| Alexa Jett 🦋 @ohhiialexa RT @gyncsm: So thankful for our guests from the "Survivors Advising Scientists Educational Program” Kim @KDRichardson924 and Ben, Tova and Casey tweeting as @UICMSTP Learn more here: https://t.co/gypjlp7s0r #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: As always, remember to tweet things of interest with hashtag #gyncsm to keep the conversation going between chats. |
| Sarah Temkin @temkins RT @womenofteal: @temkins @gyncsm @sdewdney Yes - I hope the @ASCO guidelines will help implement more testing #gyncsm |
| Rie Lopez, MPH (she/her) @RieOfLetters @uicmstp Great advice! This works when you are reading a research paper, as well. It is like your TLDR. As @ohhiialexa mentioned, just reading this section can help understand the #research better, especially when you are just getting started. #gyncsm |
| Tobey @BRCAinfo @gyncsm @KDRichardson924 @uicmstp Good job 👏 👍. Thank you #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Thanks to everyone who joined along. Save the date for our next #gyncsm chat Wed Aug 12 at 9pmET on Endometrial Cancer - Risks, Symptoms, Treatment. Wishing wellness and safety for all. |
| Alexa Jett 🦋 @ohhiialexa RT @RieOfLetters: @uicmstp Great advice! This works when you are reading a research paper, as well. It is like your TLDR. As @ohhiialexa mentioned, just reading this section can help understand the #research better, especially when you are just getting started. #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @gyncsm: Thanks to everyone who joined along. Save the date for our next #gyncsm chat Wed Aug 12 at 9pmET on Endometrial Cancer - Risks, Symptoms, Treatment. Wishing wellness and safety for all. |
| Dee Sparacio @womenofteal RT @gyncsm: As always, remember to tweet things of interest with hashtag #gyncsm to keep the conversation going between chats. |
| Dee Sparacio @womenofteal RT @gyncsm: Thanks to everyone who joined along. Save the date for our next #gyncsm chat Wed Aug 12 at 9pmET on Endometrial Cancer - Risks, Symptoms, Treatment. Wishing wellness and safety for all. |
| Dee Sparacio @womenofteal Remember to check https://t.co/Df2f7Okp35 for a transcript of the chat and resources #gyncsm |
| Ann Becker-Schutte @DrBeckerSchutte RT @womenofteal: Remember to check https://t.co/Df2f7Okp35 for a transcript of the chat and resources #gyncsm |
 | Tova Linn @tova_linn RT @gyncsm: So thankful for our guests from the "Survivors Advising Scientists Educational Program” Kim @KDRichardson924 and Ben, Tova and Casey tweeting as @UICMSTP Learn more here: https://t.co/gypjlp7s0r #gyncsm |
| Dee Sparacio @womenofteal @SHAREing webinar with Dr. Kara Long Roche of @sloan_kettering Discuss the latest developments in research and treatment on Tuesday, July 14: https://t.co/WUnN152Ift #gyncsm #MSKCC |
| Tanya Temkin @tanyaltee TIL Among other things, that scientific posters are much more information-dense than they were just a few years ago, when I designed layout for a few posters. And the conventions for presentation have evolved. #gyncsm |
| Dee Sparacio @womenofteal Stay well Teal Sisters, healthcare providers and caregivers. #gyncsm |
| Dee Sparacio @womenofteal RT @tanyaltee: TIL Among other things, that scientific posters are much more information-dense than they were just a few years ago, when I designed layout for a few posters. And the conventions for presentation have evolved. #gyncsm |
| Christina Lizaso @btrfly12 Honored to feature one of these great new modules. Amazing things happen when patient advocates, scientists and physicians come together! #gyncsm |
 | Ann Becks @AMBecks_AllBlue RT @tanyaltee: TIL Among other things, that scientific posters are much more information-dense than they were just a few years ago, when I designed layout for a few posters. And the conventions for presentation have evolved. #gyncsm |
| Dee Sparacio @womenofteal @tanyaltee I like the layout with the conclusion right there in the center #gyncsm |
| Ann Becks @AMBecks_AllBlue RT @ohhiialexa: TIL: TIL: That there are many people out there making advocacy better. I fully and truly believe that patient advocates belong in the scientific space. Education is the key here, and I’m thrilled with these modules. #GYNCSM |
| Dee Sparacio @womenofteal RT @btrfly12: Honored to feature one of these great new modules. Amazing things happen when patient advocates, scientists and physicians come together! #gyncsm |
| Matthew Katz, MD 🟦 @subatomicdoc RT @tanyaltee: TIL Among other things, that scientific posters are much more information-dense than they were just a few years ago, when I designed layout for a few posters. And the conventions for presentation have evolved. #gyncsm |
| Dee Sparacio @womenofteal Grateful for our #gyncsm co-moderators! @btrfly12 @ShannonWestin @temkins @journeycancer @DrBeckerSchutte #gyncsm |
| Christina Lizaso @btrfly12 RT @ohhiialexa: TIL: TIL: That there are many people out there making advocacy better. I fully and truly believe that patient advocates belong in the scientific space. Education is the key here, and I’m thrilled with these modules. #GYNCSM |
| Matthew Katz, MD 🟦 @subatomicdoc RT @uicmstp: T7 (8/9) Conclusions: T7 (8/9) Conclusions: The conclusions are found right in the middle in large font - designed so that they are easy to find. #gyncsm |
| Christina Lizaso @btrfly12 Thanks to everyone who listened along and contributed to tonight's #gyncsm Hope to see you around Twitter again soon. |
| Dee Sparacio @womenofteal Thanks @KDRichardson924 and @uicmstp for joining us - sharing such valuable information about posters and for developing a rogram that will benefit so many patients and advocates. #gyncsm |
| UIC MSTP @uicmstp 100% ! We hope to keep this partnership between trainees (us) and patient advocates going! We have already learned SO much! #SASEP #gyncsm -BG,TB,CB |
| Christina Lizaso @btrfly12 RT @uicmstp: 100% ! We hope to keep this partnership between trainees (us) and patient advocates going! We have already learned SO much! #SASEP #gyncsm -BG,TB,CB |
| Rie Lopez, MPH (she/her) @RieOfLetters So glad I could make it tonight. Thank you everyone. This was a fantastic topic and I loved the company, as always! #gyncsm https://t.co/6Xy9gOvvB0 |
| Dee Sparacio @womenofteal @RieOfLetters I'm glad you're OK and able to join us. Always good to see our regulars! #gyncsm |
#GynCSM content from Twitter.